Differences in 28-day mortality of severe COVID-19 patients treated with unfractionated heparin or low molecular weight heparin (LMWH) compared to control group given no anticoagulant based on SIC score
-
Mortality was significantly different among those with SIC score ≥ 4 (40.0% vs 64.2%, P = .029)
-
Mortality was not significantly different for those with SIC score < 4 (29.0% vs 22.6%, P = .419)
-
Overall mortality was not significantly different by group (30.3% vs 29.7%, P = .910).
-
Odds ratios, confidence intervals can be found in table 4 in child node
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Differences in 28-day mortality of severe COVID-19 patients treated with unfractionated heparin or low molecular weight heparin (LMWH) compared to control group given no anticoagulant based on SIC score
Differences in 28-day mortality of severe COVID-19 patients by D-dimer level among those given unfractionated heparin or low molecular weight heparin (LMWH) compared to control group given no anticoagulant.
Evaluation of other predictors of 28-day mortality pertaining to clotting factors and heparin treatment
SIC score interpretation for COVID-19
Methods for evaluating heparin effectiveness in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
Patient characteristics in study evaluating heparin effectiveness in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
Discussion for evaluating 28-day mortality of severe COVID-19 patients treated with unfractionated heparin or low molecular weight heparin (LMWH) compared to control group